Outlook Therapeutics, Inc.

Outlook Therapeutics (OTLK) shows a clean 90-day window with zero cyber incidents, bankruptcy signals, or officer departures on record. This absence of acute red flags, however, does not establish underlying stability—our detection window is recent and narrow. The full $49 Report extends analysis across 12 months of filings, quantifies shareholder dilution risk, maps the company's financing history and burn rate, and flags AI-detected stress signals in MD&A language and cash-flow patterns. The full $49 Report adds dilution risk scoring, 8-K context and precedent, 12-month cyber and governance history, and early-warning indicators derived from filing language analysis.